Patrys

Dr Samantha South represents Patrys at the European Delirium Conference in Oslo Check out the full update and join in with the conversation at: patrys.com/activity-updates/… #PAB

$PAB Q1 FY27: Cohort 1 complete, SRC green-lights Cohort 2, Yale deoxymab deal signed. Cohort 2 dosing targeted for Dec 2026. patrys.com/announcements/781… #ASX #PAB

Patrys CEO Dr Samantha South will present at the MST Biotech & Healthcare Webinar - New Discoveries on Tue 13 Oct, 2:00pm AWST / 4:00pm AEDT. Register: mstfinancial-au.zoom.us/webi… $PAB #ASX #biotech

RLS-2202 Phase 1a update → All Cohort 1 participants have now completed dosing and follow-up. Next milestone → independent SRC review in October, ahead of potential progression to Cohort 2. Patrys Completes Cohort 1 Dosing and Follow-Up #PAB#ASX #Biotech #ClinicalTrials

A major milestone for $PAB: RLS-2202 has entered human clinical evaluation. First participants dosed in our Phase 1a trial, generating human data to inform the next stage of development. Check out the full announcement at: patrys.com/announcements/774… #PAB

$PAB has established an international Clinical Advisory Committee to help guide the next stage of RLS-2202 development, as our Phase 1 program progresses. patrys.com/announcements/773… #ASXPAB #Biotech #Delirium #ClinicalTrials

Phase 1A cleared to proceed. $PAB has received HREC approval to commence its Phase 1A clinical trial of RLS-2202 Next: site activation, participant screening & enrolment First participant dosing remains on track for this quarter 📄 patrys.com/announcements/770… #ASX #PAB #Biotech

Good to see Patrys and RLS-2202 featured by Stockhead as we continue progressing toward the clinic. #Patrys #RLS2202 #Biotech #ASX stocks.apple.com/A6HPmFR4oSG…

Patrys (ASX) has appointed CMAX as the clinical trial site and Alithia as CRO for the upcoming RLS-2202 Phase 1A study. An important milestone completed as the Company advances toward first participant dosing targeted for Q3 CY2026 (subject to approvals). #Biotech #ASX

Successful Placement. A$3.2M raised. Strong investor demand reinforces our strategy. Balance sheet strengthened → Next: Execute Phase 1A clinical trial Read more 👉 asx.com.au/markets/company/P… #ASX #PAB #Biotech

$PAB | Patrys has received a rebate of $1.285 million for the 2023/2024 financial year under the Federal Government’s R&D Tax Incentive scheme. Read today’s ASX release here: bit.ly/PAB-RD-Refund $PAB #ASX #research #innovation #clinicaltrial

$PAB |Patrys has today released its Quarterly Activities Report and 4C Quarterly Cash Flow Report, for the period ended 30 June 2024. Read today’s ASX release here: bit.ly/PAB-Quarterly-Sept-20… #ASX #research #innovation #biotech #cancer #antibodies

ANNUAL REPORT | #Patrys has released its Annual Report for the 20223-24 Financial Year (FY24). See it here: bit.ly/PAB-Annual-Report-FY2… $PAB #ASX #biotech #innovation #pharma #antibodies

$PAB | #Patrys has today released its Quarterly Activities Report and 4C Quarterly Cash Flow Report, for the period ended 30 June 2024. Read today’s ASX release here: bit.ly/PAB-Quarterly-July202… #ASX #research #innovation #biotech #cancer #antibodies

$PAB | #Patrys has today released its Quarterly Activities Report and 4C Quarterly Cash Flow Report, for the period ended 31 March 2023. Read today’s ASX release here: bit.ly/PAB-Quarterly-March20… #ASX #research #innovation #biotech #cancer #antibodies

$PAB | New data from preclinical studies using deoxymabs in animal models of the autoimmune disease anti-neutrophil cytoplasmic antibody (ANCA) #vasculitis were at the 21st International Vasculitis Workshop in Barcelona overnight. Read the ASX release: bit.ly/PAB-Vasculitis-Study

$PAB | Patrys has announced that new data from preclinical studies using PAT-DX1 in animal models of ANCA vasculitis will be presented at the 21st International Vasculitis Workshop in Barcelona next month. Read today’s ASX release: bit.ly/PAB-ANCA-Vasculitis #biotech #antibodies

On World Cancer Day, we’re shining a light on global efforts to bridge gaps in cancer knowledge and treatment - all in the name of building a brighter future for patients and their loved ones. $PAB #Patrys #cancer #biotech #innovation #antibodies #clinicaltrial #WorldCancerDay

$PAB | Patrys has today released its Quarterly Activities Report and 4C Quarterly Cash Flow Report, for the period ended 31 December 2023. Read today’s ASX release here: bit.ly/PAB-Quarterly-31Dec20… #ASX #research #innovation #biotech #cancer #antibodies